Abolon was mandated by Afinum, the DACH-based private equity firm, on its acquisition of a majority stake in Swiss biotech company evitria, which provides custom antibodies for research purposes.
evitria has been conducting more than 30,000 transfections and has been producing more than 5,000 different antibodies to date. The company’s success is based on a unique, highly standardized and automatized production process that minimizes throughput times and guarantees high concentrations and quality levels, thereby perfectly addressing its customers’ need for specific, tailor-made antibodies. Its business model has allowed evitria to build a reputation of a superior biotech specialist and trustworthy outsourcing partner.
The transaction has been closed today. The enterprise value was not made publicly available.
Abolon was exclusively mandated by Afinum.
English 
Deutsch